Lan Lan

Lan Lan

Auto-generated profile, based on publicly available information

Lan Lan

Chinese Academy of Medical Sciences (CAMS) and Peking Union Medical College (PUMC) 1 Department of Etiology and Carcinogenesis, National Cancer Center/National Clinical Research Center/Cancer Hospital Beijing, China

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 May 2026 in Cancer Discovery
Verified
Journal Article
Open access
PDF file
LZLiang Zhu
Liang Zhu
XWXiaoyuan Wang
Xiaoyuan Wang
GCGuoyu Cheng
Guoyu Cheng
YLYancheng Lai
Yancheng Lai
LLLan Lan
Lan Lan
JCJiang Chang
Jiang Chang
Neoadjuvant immunotherapy improves outcomes in esophageal squamous cell carcinoma (ESCC), yet ∼70% of patients fail to respond. Pretreatment biopsies and plasma provide critical opportunities for biomarker discovery. In this study, we performed plasma proteomic profiling and identified soluble glycoprotein nonmetastatic melanoma protein B (sGPNMB) as the most elevated circulating protein in nonresponders. Mechanistically, tumor cell-derived sGPNMB suppressed CD8+ T-cell receptor signaling via the SDC4−CD148 axis to induce functional exhaustion, with secretion being required for its immunosuppressive activity. Cancer-associated fibroblast−epithelial (CAF-Epi) niches promoted SOX2 upregulation in tumor cells, transcriptionally activating GPNMB expression. In humanized patient-derived xenograft models, circulating GPNMB levels predicted response to PD-1 blockade, and GPNMB inhibition synergized with therapy. Across retrospective cohorts and a prospective clinical trial, a multimodal model combining plasma GPNMB levels, CAF-Epi niche detection, and clinical-pathologic features achieved robust predictive accuracy for immunotherapy response and survival. These findings establish a spatial-circulating biomarker framework for precision ESCC immunotherapy. Significance: Tumor-derived soluble GPNMB, transcriptionally activated by SOX2 within CAF-Epi niches, drives CD8+ T-cell exhaustion and resistance to PD-1 blockade in ESCC. Integrating circulating GPNMB levels with CAF-Epi niche features and clinical-pathologic factors, we develop and validate a clinically scalable multimodal model for predicting immunotherapy response.

1 July 2026
Verified
Other
Open access
LZLiang Zhu
Liang Zhu
XWXiaoyuan Wang
Xiaoyuan Wang
GCGuoyu Cheng
Guoyu Cheng
YLYancheng Lai
Yancheng Lai
LLLan Lan
Lan Lan
JCJiang Chang
Jiang Chang
Supplementary Figure S8. GPNMB is a therapeutic target for overcoming immunotherapy resistance

1 July 2026
Verified
Other
Open access
LZLiang Zhu
Liang Zhu
XWXiaoyuan Wang
Xiaoyuan Wang
GCGuoyu Cheng
Guoyu Cheng
YLYancheng Lai
Yancheng Lai
LLLan Lan
Lan Lan
JCJiang Chang
Jiang Chang
Supplementary Figure S6. The CAF-Epi niche and GPNMB are robust predictors of immunotherapy response across multiple cancer types

1 July 2026
Verified
Other
Open access
LZLiang Zhu
Liang Zhu
XWXiaoyuan Wang
Xiaoyuan Wang
GCGuoyu Cheng
Guoyu Cheng
YLYancheng Lai
Yancheng Lai
LLLan Lan
Lan Lan
JCJiang Chang
Jiang Chang
Supplementary Table S5. Sequences of siRNAs and primers

1 July 2026
Verified
Other
Open access
LZLiang Zhu
Liang Zhu
XWXiaoyuan Wang
Xiaoyuan Wang
GCGuoyu Cheng
Guoyu Cheng
YLYancheng Lai
Yancheng Lai
LLLan Lan
Lan Lan
JCJiang Chang
Jiang Chang
Supplementary Figure S2. GPNMB suppresses CD8⁺ T cell function in vitro

1 July 2026
Verified
Other
Open access
PDF file
LZLiang Zhu
Liang Zhu
XWXiaoyuan Wang
Xiaoyuan Wang
GCGuoyu Cheng
Guoyu Cheng
YLYancheng Lai
Yancheng Lai
LLLan Lan
Lan Lan
JCJiang Chang
Jiang Chang
Supplementary Figure S9. Characterization of predictive biomarkers in the retrospective and prospective cohorts